Company intelligence / Profile preview

Rampart Health

San Diego, California, United Statesramparthealth.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Rampart Health reported positive preliminary results from its first-in-human Phase 2 trial ("Abscopal 5001") of MITI in metastatic cancer. The treatment was safe and well tolerated as an outpatient procedure. Disease control rate was observed at 77% (partial response in ~39%, stable disease in ~39%), and the abscopal effect—regression of untreated metastases—was seen in about a third of patients. No grade 4 or higher adverse events were reported.

Therapeutic areas: Oncology
Modalities: Multiplex intra-tumoral immunotherapy (MITI)Combination of cryo-ablation, intra-tumoral checkpoint inhibitors, and local chemotherapy
Industry: Biotech

Drug pipeline

1 asset

AbscopalRx5001

Unknown

Beyond the preview

Go deeper on Rampart Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rampart Health.

Explore the full profile